Compare Aurora Cannabis Inc (ACB) vs Amgen, Inc. (AMGN) Price & Performance

Aurora Cannabis IncTrade

Amgen, Inc.Trade

Price performance (Past 24H)

Key statistics

Aurora Cannabis Inc vs Amgen, Inc. — how do they compare? Aurora Cannabis Inc trades at $3.44 (market cap $223.59M), while Amgen, Inc. trades at $412.21 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 1002.5× Aurora Cannabis Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Aurora Cannabis Inc pays none. Which is the better fit depends on your goals.

	ACB	AMGN
Market Cap	$223.59M	$224.14B
Sector	Health	Health
52-Week High	$6.23	$417.20
52-Week Low	$2.58	$271.18
Enterprise Value	$168.09M	$267.45B
Dividend Yield	—	2.43%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ACB

Aurora Cannabis reviews unsolicited $4/share takeover bid from Curaleaf, no decision yet.PRNewsWire · 20 hours agoNeutral Curaleaf launches hostile bid to acquire Aurora Cannabis at $4 per share, offering shares plus cash.Proactive Investors · 20 hours agoBullish Curaleaf offers to buy Aurora Cannabis with a 45% premium, aiming to create a leading global cannabis platform.PRNewsWire · 1 day agoBullish View details →

AMGN

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish View details →

About Aurora Cannabis Inc

Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).